Overall, the available data, i.e., the findings of DDX41 mutations being of frequent germline origin, representing leukemia-initiating events, and the paucity of co-occurring molecular and cytogenetic lesions, provide strong evidence that AML with mutated DDX41 may represent a clinico-pathologic entity of AML. This evidence concerns the gene DDX41 and leukemia.